Zhejiang Jiuzhou Pharmaceutical Co., Ltd

Equities

603456

CNE100001W36

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
14.72 CNY -1.47% Intraday chart for Zhejiang Jiuzhou Pharmaceutical Co., Ltd -4.17% -39.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jiuzhou Pharmaceutical Gets Nod to Market Sitagliptin Metformin Tablets; Shares Drop 4% MT
Ruibo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Tranche Update on Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback Plan announced on January 5, 2024. CI
Jiuzhou Pharma to Build $42 Million CRO Platform in Japan MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd announces an Equity Buyback for CNY 100 million worth of its shares. CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd authorizes a Buyback Plan. CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it has received CNY 100 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive CNY 100 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Jiuzhou Pharmaceutical Logs Double-Digit Growth in H1 Earnings on Expanded CDMO Operations MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jiuzhou Pharma to Set Up Singapore Subsidiary MT
Ruihua Pharmaceutical Co., Ltd. announced that it has received CNY 185 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Jiuzhou Pharma Gets Drug Registration Certificate for Carbamazepine Sustained-release Tablets MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd(SHSE:603456) dropped from Shanghai Stock Exchange 180 Value Index CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd(SHSE:603456) dropped from SSE 180 Index CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback announced on September 1, 2022 has closed with 2,871,000 shares, representing 0.33% for CNY 99.99 million. CI
Tranche Update on Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback Plan announced on September 1, 2022. CI
Chart Zhejiang Jiuzhou Pharmaceutical Co., Ltd
More charts
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.72 CNY
Average target price
23.42 CNY
Spread / Average Target
+59.12%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603456 Stock
  4. News Zhejiang Jiuzhou Pharmaceutical Co., Ltd
  5. Jiuzhou Pharma to Purchase Factory From Sandoz China for $26 Million